Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.

More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

Not a lot of people know about psoriasis which is why several myths and misconceptions about the condition continue to ...

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

Biologics are more targeted than other psoriasis treatments. They’re also more expensive, and you take them less frequently. Doctors usually prescribe them for moderate to severe psoriasis.

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the population and is mediated ...

The study revealed that younger patients (16-24 years) with moderate-to-severe psoriasis were more likely to discontinue TNF ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

In a new study, researchers at Case Western Reserve University School of Medicine have determined that a protein called NF-kB ...

In a new study, researchers have determined that a protein called NF-kB c-Rel can intensify the symptoms of psoriasis when activated by signals from the body's immune system. Understanding how 'c-Rel' ...

Published results showed “Latine” patients with psoriasis in the U.S. have unique experiences with their disease and ...

Discover a recent study that has provided valuable insights into the experiences of Latine patients living with moderate to ...